XTRA:DBK
XTRA:DBKCapital Markets

A Look at Deutsche Bank (XTRA:DBK) Valuation Following New Bond Issuance and Key Leadership Appointment

Deutsche Bank (XTRA:DBK) has drawn extra attention lately, after unveiling a string of new bond offerings and naming Vivienne Chia as its new global head of private bank investment solutions. The mix of debt issuance and a high-profile executive hire gives investors more to consider as the bank moves into December. See our latest analysis for Deutsche Bank. The steady rollout of new bonds and Chia’s high-profile arrival are occurring at a time of impressive momentum for Deutsche Bank. The...
XTRA:HAG
XTRA:HAGAerospace & Defense

Will Hensoldt (XTRA:HAG) Use Digitalisation to Strengthen Its Defense Technology Leadership?

On November 25, 2025, Hensoldt AG presented at PMRExpo 2025, where Oberst d.R. Sven Heursch, Head of Software-defined Defence and Head of Digitalisation, discussed the company's latest advancements and strategies in defense technology. The presentation focused on software-defined defense and digitalisation, highlighting areas that are increasingly vital for growth in the defense sector. We’ll explore how Hensoldt’s spotlight on software-defined defense at PMRExpo 2025 could influence its...
XTRA:TKMS
XTRA:TKMSAerospace & Defense

ThyssenKrupp Marine Systems (XTRA:TKMS): Valuation Spotlight Following Canadian Submarine Bid Progress

ThyssenKrupp Marine Systems (XTRA:TKMS) is drawing increased attention this week as it teams up with Kongsberg in a high-profile bid to supply Canada with a new fleet of Arctic-capable submarines. The project's momentum and its focus on long-term partnerships have fueled discussion among investors curious about its potential impact. See our latest analysis for TKMS & Co KGaA. After an early-year rally, momentum for TKMS & Co KGaA has faded. The stock has experienced a 21% decline in its...
XTRA:AT1
XTRA:AT1Real Estate

Aroundtown (XTRA:AT1) Rallies to Net Profit on €615m One-Off Gain, Challenging Sustainability Narratives

Aroundtown (XTRA:AT1) just reported its Q3 2025 results, posting revenue of €389.9 million and basic EPS of €0.17 for the quarter. The company has seen revenue range from €418.1 million in Q3 2024 to €389.9 million most recently, while EPS figures have fluctuated between €0.09 and €0.17 over the past year. Investors now have fresh margins data to digest as they size up the overall performance and what it signals for the business's current trajectory. See our full analysis for...
XTRA:RWE
XTRA:RWERenewable Energy

RWE (XTRA:RWE): Examining Valuation After a 6% Share Price Gain This Month

RWE (XTRA:RWE) has seen some interesting movement in its share price over the past month, gaining nearly 6%. For investors, this raises questions about what is driving the recent momentum and how sustainable it might be. See our latest analysis for RWE. RWE's steady climb is drawing attention, especially with a year-to-date share price return of almost 47% and a total shareholder return of 41% over the past 12 months. While there have been small swings in recent days, this overall momentum...
XTRA:UN0
XTRA:UN0Renewable Energy

Uniper (XTRA:UN0): Assessing Valuation as Shares Rebound 10% This Week

Uniper (XTRA:UN0) shares have been trending modestly higher this week, with the stock up just over 10% in the past week. Investors are watching for signs of operational stability and possible valuation opportunities as the company navigates a changing energy landscape. See our latest analysis for Uniper. Uniper’s share price may have rebounded over 10% this week, but this momentum has yet to offset its longer-term slide. While short-term confidence appears to be building after months of...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Bayer (XTRA:BAYN): Valuation Insights Following Strong Phase III Asundexian Stroke Trial Results

Bayer (XTRA:BAYN) is in the spotlight after reporting successful topline results from its Phase III OCEANIC-STROKE trial for asundexian. The investigational anticoagulant significantly reduced the risk of ischemic stroke without an increase in major bleeding events. See our latest analysis for Bayer. Bayer’s upbeat OCEANIC-STROKE trial results for asundexian come amid a period of heightened momentum for the stock. After surging on the news, Bayer’s 7-day share price return jumped 12.4%, with...